National Cancer Institute (NCI) - Recruiting 18 years or older. - Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on First-Line VEGFR-Targeted Therapy.
Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older. - A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma.
National Cancer Institute (NCI) - Recruiting 2 years to 18 years. - A Phase 1 Study of XL184 (Cabozantinib, IND# 116059) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors.
National Cancer Institute (NCI) - Recruiting 2 years to 30 years. - A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (IND# 69896) in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma.